<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01187108</url>
  </required_header>
  <id_info>
    <org_study_id>10-0078</org_study_id>
    <nct_id>NCT01187108</nct_id>
  </id_info>
  <brief_title>Study of Cobalt's Role in Excessive Erythrocytosis Among High Altitude Dwellers in Cerro de Pasco, Peru</brief_title>
  <acronym>CoCMS</acronym>
  <official_title>Randomized Controlled Trial of N-acetylcysteine and Acetazolamide in Treatment of Chronic Mountain Sickness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universidad Peruana Cayetano Heredia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jackson, Brian, M.S.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Thomas H Maren Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic mountain sickness is characterized by excessive red blood cell production which
      causes sludging of the vascular system. This high viscosity blood causes heart failure,
      cognitive dysfunction, and strokes. The investigators hypothesize that cobalt which has been
      previously been shown to be an environmental pollutant worsens the overproduction of red
      blood cells. The investigators plan to conduct a 6 week trial in which acetazolamide (already
      shown to improve chronic mountain sickness) and N-acetylcysteine (a drug that removes cobalt
      from the blood) are evaluated in their potential to improve chronic mountain sickness.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Hematocrit, or fraction of plasma occupied by cellular elements at week 8</measure>
    <time_frame>Baseline and week 8</time_frame>
    <description>Spun hematocrit measured on portable machine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in arterial blood gas values at week 8</measure>
    <time_frame>Baseline and week 8</time_frame>
    <description>Analyzed using portable machine. The values analyzed include serum pH, partial pressure of carbon dioxide, partial pressure of oxygen, and serum bicarbonate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Erythropoietin at week 8</measure>
    <time_frame>Baseline and week 8</time_frame>
    <description>Serum hormone that stimulates red blood cell production</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in serum and urine Cobalt at day 3</measure>
    <time_frame>Baseline and day 3</time_frame>
    <description>Will calculate spot clearance of cobalt</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in baseline urine protein at 8 weeks</measure>
    <time_frame>Baseline and week 8</time_frame>
    <description>Ratio of urine total protein to urine creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in baseline Chronic mountain sickness score at 8 weeks</measure>
    <time_frame>Baseline and week 8</time_frame>
    <description>Chronic Mountain Sickness Score Absent Mild Moderate Severe Headache 0 +1 +2 +3 Dizziness 0 +1 +2 +3 Failing Memory 0 +1 +2 +3 Fatigue 0 +1 +2 +3 Breathlessness 0 +1 +2 +3 Sleep disturbances 0 +1 +2 +3 Tinnitus 0 +1 +2 +3 Anorexia 0 +1 +2 +3 Cyanosis of lips, face, or fingers 0 +1 +2 +3 Hyperemia or prominent capillaries conjunctivae or laryngopharynx 0 +1 +2 +3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in baseline Serum electrolytes at day 3, 14 and week 8</measure>
    <time_frame>Baseline and Days 3, 14, and week 8</time_frame>
    <description>Electrolytes, specifically monitoring serum potassium to treat serious hypokalemia (serum potassium &lt; 3.0 meQ/L).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Erythrocytosis</condition>
  <condition>Mountain Sickness</condition>
  <arm_group>
    <arm_group_label>Placebo pills</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Acetazolamide alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>N-acetylcysteine alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination of N-acetylcysteine and acetazolamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetylcysteine</intervention_name>
    <description>NAC 600 mg oral once daily</description>
    <arm_group_label>N-acetylcysteine alone</arm_group_label>
    <arm_group_label>Combination of N-acetylcysteine and acetazolamide</arm_group_label>
    <other_name>Given in gel capsules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetazolamide</intervention_name>
    <description>Acetazolamide 250 mg oral once daily</description>
    <arm_group_label>Acetazolamide alone</arm_group_label>
    <arm_group_label>Combination of N-acetylcysteine and acetazolamide</arm_group_label>
    <other_name>Given in gel capsules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo pills</intervention_name>
    <description>1 (or 2 in the placebo group) empty gel capsules</description>
    <arm_group_label>Placebo pills</arm_group_label>
    <arm_group_label>Acetazolamide alone</arm_group_label>
    <arm_group_label>N-acetylcysteine alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males over 17 years of age

          -  Hematocrit &gt; 70%

          -  Chronic Mountain Sickness score (CMS) &gt; 6

          -  Able to give informed consent and follow instructions in written Spanish

        Exclusion Criteria:

          -  CMS &gt; 15

          -  Underlying lung disease, smoking, or oxygen therapy

          -  Asthma (bronchospasm can be caused by N-acetylcysteine)

          -  Phlebotomy in last 3 months

          -  h/o adverse reaction to acetazolamide or N-acetylcysteine
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Johnson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado Denver Health Sciences Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abdias Hurtado, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad Peruana Cayetano Heredia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Fuquay, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Colorado Denver Health Sciences Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chronic mountain sickness clinic</name>
      <address>
        <city>Cerro de Pasco</city>
        <state>Pasco</state>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Peru</country>
  </location_countries>
  <reference>
    <citation>Jefferson JA, Escudero E, Hurtado ME, Pando J, Tapia R, Swenson ER, Prchal J, Schreiner GF, Schoene RB, Hurtado A, Johnson RJ. Excessive erythrocytosis, chronic mountain sickness, and serum cobalt levels. Lancet. 2002 Feb 2;359(9304):407-8.</citation>
    <PMID>11844517</PMID>
  </reference>
  <reference>
    <citation>Jefferson JA, Escudero E, Hurtado ME, Kelly JP, Swenson ER, Wener MH, Burnier M, Maillard M, Schreiner GF, Schoene RB, Hurtado A, Johnson RJ. Hyperuricemia, hypertension, and proteinuria associated with high-altitude polycythemia. Am J Kidney Dis. 2002 Jun;39(6):1135-42.</citation>
    <PMID>12046023</PMID>
  </reference>
  <reference>
    <citation>Richalet JP, Rivera-Ch M, Maignan M, Privat C, Pham I, Macarlupu JL, Petitjean O, Le√≥n-Velarde F. Acetazolamide for Monge's disease: efficiency and tolerance of 6-month treatment. Am J Respir Crit Care Med. 2008 Jun 15;177(12):1370-6. doi: 10.1164/rccm.200802-196OC. Epub 2008 Apr 3.</citation>
    <PMID>18388356</PMID>
  </reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2010</study_first_submitted>
  <study_first_submitted_qc>August 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2010</study_first_posted>
  <last_update_submitted>May 13, 2015</last_update_submitted>
  <last_update_submitted_qc>May 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cobalt</keyword>
  <keyword>Excessive Erythrocytosis</keyword>
  <keyword>Monge's Disease</keyword>
  <keyword>Acetazolamide</keyword>
  <keyword>N-acetylcysteine</keyword>
  <keyword>Altitude Sickness</keyword>
  <keyword>Chronic Mountain Sickness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Altitude Sickness</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
    <mesh_term>Acetazolamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

